CtBPs form NADH-sensitive chromatin-modifying complexes, which link cellular metabolism to gene transcription. They also function in the cytoplasm to regulate Golgi fissioning; their inhibition can consequently cause a Golgidependent checkpoint in G 2 . We have recently identified a novel role of CtBPs in the maintenance of mitotic fidelity; inhibition of CtBP synthesis resulting in reduced association of aurora B with mitotic chromatin and aberrant segregation of chromosomes. Here, we demonstrate that it is the interaction of CtBPs with transcriptional regulators and/or chromatin-modifying enzymes in the cell nucleus, rather than their role in Golgi fission, which is critical for the maintenance of mitotic fidelity.
Introduction
CtBPs (CtBP1 and CtBP2) were identified as cellular binding partners of adenovirus E1A proteins. Deletion of the CtBP-binding region at the C terminus of E1A modifies E1A's activity as a transforming oncogene (Boyd et al., 1993; Schaeper et al., 1995) . CtBPs function as transcriptional co-repressors by forming a chromatinmodifying complex that is recruited to promoters via its association with DNA-binding transcription factors (Shi et al., 2003; Chinnadurai, 2007) . Many CtBP-binding proteins, including E1A, transcription factors and class II histone deacetylases (HDACs) contain a consensus PxDLS CtBP-binding motif (Chinnadurai, 2007) . Consequently, CtBPs play a key role in diverse cellular processes, including tumour cell survival, cell migration, epithelial mesenchymal transition and cellular senescence Chinnadurai, 2009) . Additionally, CtBP1, or specifically a splice form termed CtBP3, BARS or CtBP1-S, was identified as a cytoplasmic lipid-binding protein important in the maintenance of the Golgi apparatus. Ablating the cytoplasmic function of CtBPs can result in the failure of Golgi fission before mitosis, and consequent activation of a Golgi-dependent cell cycle checkpoint in G 2 phase (Hidalgo Carcedo et al., 2004; Colanzi et al., 2007) . Thus, CtBPs are multifunctional proteins with distinct roles in the nucleus and cytoplasm.
CtBPs have a well-described pro-survival role; ctbp1
À/À fibroblasts are hypersensitive to stress-induced apoptosis (Grooteclaes et al., 2003) , and small interfering RNA (siRNA) to CtBP causes p53-independent apoptosis in cancer-derived cell lines Paliwal et al., 2006; Bergman et al., 2009) . CtBPs can promote cell survival through multiple mechanisms; including the suppression of anoikis (Grooteclaes et al., 2003) , repression of specific pro-apoptotic genes (Kovi et al., 2010) and, as we have demonstrated, maintenance of mitotic fidelity (Bergman et al., 2009) . CtBPs are required for the optimal association of aurora B with chromatin during mitosis; siRNAs to CtBPs resulting in chromosome segregation defects or failure of the abscission phase of cytokinesis, consistent with its effects on aurora B. Subsequent to an aberrant mitosis, CtBP-siRNA-treated cells either undergo a p53-dependent post-mitotic arrest or, if p53 is inactive, initiate apoptosis. In those experiments, there were no gross effects of CtBP siRNA on Golgi morphology, suggesting that the aberrant mitotic phenotype might not be a consequence of abnormal Golgi maintenance in these CtBP-compromised cells (Bergman et al., 2009) . Here, we have directly addressed whether it is the nuclear or cytoplasmic roles of CtBPs that are important for their regulation of mitotic fidelity, using microinjection of dominant-negative CtBP protein fragments into distinct cellular compartments.
Results
Structural and mutational analysis of CtBPs have identified discreet functional domains within the proteins; the N terminus forms a hydrophobic cleft that contacts the PxDLS motif in many of its partner transcriptional regulators, and the core central domain undergoes NAD þ /NADH-dependent dimerization, which is required for the assembly of the chromatinmodifying complex (Nardini et al., 2003; Quinlan et al., 2006; Chinnadurai, 2007; Kuppuswamy et al., 2008) . CtBP chromatin-modifying complexes are readily detectable in proliferating cancer cells in culture (Shi et al., 2003) , and there is evidence that their formation is increased under conditions of increased glycolysis, for example, in response to hypoxia (Zhang et al., 2002) . The C-terminal domain makes secondary interactions with some PxDLS-containing factors (Kuppuswamy et al., 2008) and is also the minimal lipid interaction domain (Yang et al., 2008) . Dimerization of CtBP molecules is required for the formation of an active chromatin-modifying complex (Kuppuswamy et al., 2008) ; we reasoned, therefore, that an N-terminal fragment of CtBP lacking the dimerization domain would act as a dominant negative by binding components of the CtBP repression complex and preventing their interaction with CtBP dimers. This region does not bind lipids (Yang et al., 2008) , so would not be predicted to affect CtBP-dependent Golgi fission. The N terminus of CtBP2 was used, as this also contains a nuclear localization/retention motif (NLS, amino acids 8-13) .
When expression constructs encoding amino acids 1-119 of CtBP2 fused to EGFP are transfected into MCF-7 cells, the fusion protein localizes primarily to the nucleus. This localization is dependant upon the NLS, as a protein lacking amino acids 4-14 is localized primarily in the cytoplasm ( & Figure 1a ). Immunoprecipitation analysis from CtBP2(1-119)EGFP-transfected cells clearly shows that this fusion protein binds a representative PxDLS-motifcontaining protein, adenovirus E1A (Figure 1b) . Furthermore, consistent with our previous data from in vitro assays (Mirnezami et al., 2003) , it also binds HDM2, which lacks a PxDLS motif. The fusion protein lacking amino acids 4-14 retained E1A-binding activity, but bound less HDM2 (Figure 1b) . Reduced HDM2 binding was not merely a consequence of the loss of nuclear localization, as it was recapitulated using recombinant proteins in vitro (Figure 1c) . Thus, in addition to acting as a nuclear retention sequence, amino acids 4-14 of CtBP2 are also involved in its interaction with HDM2 and; therefore, CtBP2 (1-119)EGFP has the potential to disrupt CtBP2-HDM2 interactions as well as interactions of CtBPs with PxDLS-containing factors.
To establish the consequence of introducing CtBP2(1-119)EGFP into cells, MCF-7 cells were transfected with either EGFPN1 vector, CtBP2 (1-119)EGFP, or CtBP2(1-119D4-14)EGFP. This cell line was chosen as we have previously used it to extensively characterize the effects of CtBP siRNA on mitotic fidelity (Bergman et al., 2009 ). We noted a high proportion of rounded cells after transfection with CtBP2(1-119)EGFP compared with either CtBP2 (1-119D4-14)EGFP or the EGFPN1 vector. However, levels of expression of the fusion proteins were very low compared with EGFP alone, making direct analysis of this effect problematic. A DsRed expression vector was thus co-transfected to allow unbiased analysis. Figure 2a shows that 48 h post-transfection, the percentage of DsRad þ ve cells that had a rounded phenotype was 49.1% ± 4.4 with EGFP alone, and 83.3% ± 3.2 when CtBP2(1-119)EGFP was transfected. This was reduced to 59.9%±6.1 in CtBP2(1-119D4-14)EGFP-transfected cells. This clearly shows that this cell-rounding phenotype induced by the dominant-negative CtBP is largely dependant upon its inclusion of amino acids 4-14. However, it was unclear from these assays as to what the specific phenotype of these rounded cells was. To clarify this, we performed fluorescence time-lapse video microscopy of cells in the period 24-48 h post-transfection. Only cells that, at the beginning of the time period, displayed both red fluorescence and a flattened morphology characteristic of viable interphase cells were analysed, and their fate determined ( Figure 2b ). A total of 38.7% of CtBP2(1-119)EGFP-transfected cells rounded up during the 24 h imaging period, compared with only 8.3 and 17.9% with EGFP and CtBP2(1-119D4-14)EGFP, respectively. The rate of cell death remained largely unchanged between all the three constructs. After expression of CtBP2(1-119)EGFP, no completed mitoses were recorded, thus CtBP2 (1-119)EGFP induces cell cycle arrest. This is broadly consistent with our previous analyses of this cell line, that is, CtBP siRNA causes both an extended period of transit through mitosis and a post-mitotic G 1 arrest (Bergman et al., 2009 ). However, we were unable to determine what proportion of cells at the start of the experiment might have already entered G 1 arrest. We were also concerned that the relatively high occurrence of cell rounding in the control-transfected cells indicated stress induced by the necessarily high amount of transfected plasmid. Thus, although transfection experiments clearly demonstrated an important role for amino acids 4-14, and thus potentially nuclear localization, in the effects of this dominant-negative CtBP construct, an alternative approach was required to resolve these two experimental limitations.
To obviate the stress induced by plasmid transfection, GST-CtBP2(1-110) and GST-CtBP2(1-110D4-14) (henceforth termed GST-CtBP DN and GST-CtBP DN DNLS) were expressed in E. coli and purified to enable their direct introduction into cells via microinjection. To permit the reliable analysis of the effects of GST-CtBP DN on the first mitosis post-microinjection, we decided to microinject cells at a defined time after release from serum-starvation-induced G 1 arrest. Optimization of the conditions for cell synchronization and release is shown in Figure 3 . After 48 h serum starvation, X80% cells accumulated in G 1 . Following subsequent re-stimulation with serum, it took approximately 30 h for the first cells (Figures 3a  and b) . Live cell imaging showed conclusively that this was due to the failure of abscission and generation of tetraploid G 1 progeny in 425% of all the mitoses (Figure 3c ). This was consistent with our previous analysis of asynchronous cultures (Bergman et al., 2009) . As CtBP functions can be regulated by hypoxia, we also asked whether CtBPs are also required for the maintenance of mitotic fidelity in hypoxic cells. Cells were synchronized, released and transfected with siRNA as in Figure 3 , and 24 h after transfection, were cultured for a further 30 h in either normoxia (B20% O 2 ) or hypoxia (1% O2). Cells were then fixed, and analysed for the presence of micronuclei, as a marker of CtBPsiRNA-induced aberrant chromosomal segregation in mitosis (Bergman et al., 2009) . CtBP knockdown induced micronuclei formation equally in cells grown under normal conditions (control siRNA 8.7%, CtBP siRNA 22.1%) and under hypoxia (control siRNA 9.9%, CtBP siRNA 23.9%). The above siRNA experiments established appropriate experimental conditions for microinjection of cells, which was performed 20 h after serum re-stimulation, although the cells are exiting G 1 . Cells were initially injected into the cytoplasm with either GST-CtBP DN , GST-CtBP DN DNLS or GST control. Dextran-FITC was co-injected to allow cells to be followed for a further 65 h by fluorescent live cell imaging. Figure 4A shows that this approach had minimal non-specific toxicity to Sub-G 1 -containing particles were never greater than 7.5% of all the detected events, and their frequency was not affected by CtBP siRNA. (c) Cells were monitored by live cell imaging over the period 4-68 h post-serum re-stimulation. The percentage of cells in which the first event was either mitosis or death was recorded. The cells that underwent mitosis were subjected to further analysis, as indicated.
Nuclear CtBPs regulate mitotic fidelity CN Birts et al the cells. The ability of cells to complete at least one mitosis in the imaging period was also not substantially affected by the GST microinjections ( Figure 4A) , nor was the time at which mitosis occurred substantially affected (not shown). Compared with injection with GST, neither GST-CtBP DN nor GST-CtBP DN DNLS further increased cell death or reduced the ability of cells to enter a first mitosis. However, of the mitotic events that did occur, GST-CtBP DN caused a significant (Po0.0001) increase in those that were aberrant, that is 27.7% compared with only 2.5% in non-injected or GST-injected cells ( Figure 4B ). Mitotic events were scored as aberrant if there was failed abscission, extended rounding during mitosis or the death of one or both daughter cells directly after mitosis ( Figure 4C ). This mitotic phenotype was dependant upon amino acids 4-14 in CtBP DN as only 5.9% of the mitoses were aberrant when GST-CtBP DN DNLS were injected (Po0.0001 compared with CtBP DN ) ( Figure 4B ). Thus, either functions of CtBPs within the nucleus or proteinprotein interactions made by amino acids 4-14 of CtBP2 are critical for mitotic fidelity. Finally, when the fate of the daughter cells from the first mitosis was analysed, we found that, although in GST-injected cells, at least one of the two cells went on to divide again within the imaging period in 25.6% of cases; this figure was reduced to 3.5% in the GST-CtBP DN -injected cells ( Figure 4B ). This was also seen with the siRNA experiment (Figure 3c) , and is consistent with CtBPcompromised MCF-7 cells undergoing a post-mitotic, p53-dependent G 1 arrest with 2-4N chromosome content (Bergman et al., 2009 ). To determine whether the CtBP DN -induced phenotype was dependant upon its nuclear localization, or other functions of amino acids 4-14, proteins were injected directly into the nucleus of cells (Figures 5a and b) . Compared with cytoplasmic injection, nuclear injection had a greater non-specific effect on inhibition of mitosis, and deaths were also marginally higher. However, of the GST controlinjected cells that entered mitosis, only 6.3% failed to complete it normally. Again, similarly to cytoplasmic injection, 40% of the mitoses in GST-CtBP DN -injected cells were aberrant (P ¼ 0.02, compared with GST alone). When GST-CtBP DN DNLS was injected directly into the nucleus, 28.6% (no significant difference compared with CtBP DN ) were aberrant, that is, when CtBP DN DNLS is delivered directly to the nucleus, it retains the ability to induce aberrant mitosis. Therefore, it is primarily the nuclear localization conferred by amino acids 4-14, rather than its ability to interact with proteins such as HDM2, that is critical for the inhibition of CtBP-dependent mitotic fidelity by CtBP DN . The above results are consistent with a requirement for an active CtBP transcriptional repression complex to be present in the nucleus in interphase, in order to maintain the fidelity of the subsequent mitosis. This conclusion is based on the assumption that the key mechanism of action of CtBP DN is to disrupt the interaction of CtBPs with PxDLS-containing transcription factors or histone-modifying enzymes. To test this assumption, we generated GST-CtBP DN V72R. V72 in CtBP2 is a critical residue in the PxDLS-binding domain, and its mutation to arginine (or mutation of the equivalent residue in CtBP1) has been clearly demonstrated by independent research groups to abrogate binding to PxDLS-containing proteins, including both chromatin-modifying enzymes and DNA-binding transcription factors (Nardini et al., 2003; Quinlan et al., 2006; Kuppuswamy et al., 2008) . Thus, this mutant of CtBP DN would be unable to effectively compete with CtBPs for binding to PxDLS-motif-containing proteins. As shown in Figure 5c , in contrast to GST-CtBP DN , there is no significant difference in the proportion of cells that have mitotic aberrations between those injected with GST-CtBP DN V72R, and those injected with GST alone. In a separate analysis of the effects of CtBP DN on the spindle assembly checkpoint, we quantified the length of time spent by each microinjected cell in mitosis ( Figure 5d) ; control injected cells spent an average of 1.3 h in mitosis, CtBP DN and CtBP DB V72R spent 3.2 and 1.6 h, respectively. Together these data confirm that the binding of CtBPs to PxDLS-containing factors in the nucleus is critical for CtBPs' role in the maintenance of mitotic fidelity. 
Discussion
In summary, therefore, CtBPs are multi-functional proteins with at least two distinct roles; in the nucleus as a scaffold protein for the formations of multi-protein complexes involved primarily in transcriptional repression and in the cytoplasm in the fission of Golgi tubules. Inhibition of CtBP synthesis using approaches such as siRNA has identified a role of CtBPs in the regulation of mitotic fidelity (Bergman et al., 2009 ), but does not distinguish which of the two distinct functions of CtBPs are involved in this phenotype. The dominant-negative approach we have used here has firstly recapitulated the mitotic phenotype induced by CtBP siRNA, thus further establishing the role of CtBPs in the control of mitotic fidelity. We have also clearly demonstrated that CtBP function in the nucleus is critical for the regulation of mitotic fidelity, as are its interactions with cellular factors that associate with the PxDLS-binding cleft. Previous studies have successfully used a similar dominant-negative approach to probe the role of CtBPs in Golgi maintenance, for example, (Hidalgo Carcedo et al., 2004) in contrast to the approach we have used here, these studies included the C-terminal domain of CtBP in their dominant-negative constructs, which has the potential to disrupt the interaction of full length CtBPs with lipids, and hence inhibit CtBP-dependent Golgi fission (Yang et al., 2008) .
CtBPs function in the nucleus to form a chromatinmodifying complex, which includes HDACs 1 and 2 amongst its core constituents (Shi et al., 2003; Kuppuswamy et al., 2008) . Experimentally, the use of HDAC inhibitors has shown the ability of CtBPs to repress transcription to be at least partially HDAC dependant (Shi et al., 2003) . Interestingly, in addition to their effects on gene transcription, HDAC inhibitors also induce effects on mitotic fidelity that are highly comparable with those we observe upon inhibition of CtBP expression or targeting of the CtBP chromatinmodifying complex. These effects include activation of the spindle assembly checkpoint, aberrant chromosomal segregation, failure of cytokinesis and reduced association of chromosomal passenger proteins with mitotic chromatin (Stevens et al., 2008; Eot-Houllier et al., 2009) . At present, the mechanisms underlying these effects of HDACs are not known, and may be either through regulation of gene transcription or through direct modification of centromeric chromatin. It is interesting to note that, to disrupt mitosis, HDAC inhibitors must be applied in S phase, additions later in the cell cycle fail to have this effect (Warrener et al., 2003) . Although we have not directly addressed which cell cycle phase CtBPs are required to maintain mitosis, the requirement for CtBP DN to either contain an NLS or be injected into the nucleus strongly suggests the requirement for CtBPs is also in interphase, before the breakdown of the nuclear membrane. Mitotic fidelity is thus dependant upon both HDACs and an intact CtBP chromatin-modifying complex; further dissection of the mechanism of regulation of mitosis by these proteins will be required to establish whether recruitment of HDACs by CtBPs is required for a normal mitotic phenotype.
Targeting chromosome segregation during mitosis may be an important mechanism of the anti-cancer activity of HDAC inhibitors (Eot-Houllier et al., 2009) . Other strategies to target the spindle assembly checkpoint, such as the use of aurora B inhibitors, are also under investigation as potential therapeutic strategies (Ditchfield et al., 2005) . The disruption of CtBP chromatin-modifying complexes in order to disrupt mitotic fidelity may be a similarly valid approach, particularly given the other known tumour-promoting activity of CtBPs (Chinnadurai, 2009 ), such as suppression of senescence (Mroz et al., 2008) and apoptosis (Kovi et al., 2010) as well as enhancement of invasion (Chen et al., 2008) . One concern with such an approach is the potential effects on normal cells; we previously showed that siRNA-targeting CtBPs induce mitotic aberrations in cultured non-transformed fibroblasts, in addition to a panel of breast cancer cell lines (Bergman et al., 2009) . It may be that, in vivo increased CtBP abundance in certain tumours (Phelps et al., 2009) or potentially increased CtBP chromatin-modifying complex formation in hyper-glycolytic tumour cells (Zhang et al., 2002) may result in selective dependency upon CtBPs for mitotic fidelity in tumours compared with normal tissues; however, experiments in which specific CtBP functions are inactivated in adult cells in vivo would be required to address these questions. Importantly, however, in the case of aurora inhibitors, which do show some toxicity due to effects on neutrophils, cellular toxicity can be overcome by arrest of normal cells with low doses of a p53-activating agent (Cheok et al., 2010) . We have previously shown that, in breast cancer cells, activation of wild-type p53 protects CtBP-siRNA-treated cells from dying, whereas cells with mutant p53 or p53 suppressed by siRNA, exhibit substantial apoptotic cell death. Hence, from these experiments, tumour cells in which the p53 response is inactive show clear selectivity for a dependence upon CtBPs for their survival. CtBPs may constitute an important new target for the therapy of human diseases such as cancers (Chinnadurai, 2009) ; the availability of approaches to selectively disrupt the distinct functions of CtBPs will surely prove invaluable in future studies to determine this potential of these proteins.
Materials and methods
Cell culture, analysis of cellular DNA content, micronuclei counting and time-lapse video microscopy was performed essentially as in Bergman et al. (2009) except that time-lapse images were captured every 30 min. When cells were cultured in 1% O 2 , 94% N 2, 5 % CO 2 , a modular incubator chamber (Billups-Rothenberg, Del Mar, CA, USA) was used. CtBP2(1-119)EGFP expression constructs and the analysis of the expressed fusion proteins has been described . siRNA targeting, a common region in both CtBP1 and CtBP2, has been described previously (Bergman et al., 2009) and was transfected at 25 nM using Interferin reagent (Polyplus
